The abstract, titled “An Interim Menopause Sub-Analysis of the POMPOM Study Evaluating the Efficacy of the Milli Expanding Dilator as a Treatment for Achieving Intercourse,” highlights promising results in women aged 50 and older using the Milli vaginal dilator, an FDA-cleared device designed to treat vaginismus and dyspareunia.

When asked to describe any impact that Milli has had on their sex life, one POMPOM participant reported, “My sex life is much better, and I really AM NOT too old! :).”

This sub-analysis compared outcomes between women over and under 50 years of age after three months of self-directed use of Milli dilation therapy. Both groups showed appreciable improvements in pain, sexual function, and progress toward achieving vaginal intercourse.

The 50+ cohort demonstrated greater improvements from their baseline in four out of six subdomains of the Female Sexual Function Index (FSFI), most notably, the satisfaction subdomain improved by 64.7% (50yo+) compared to 36.6% (<50yo).

“The findings are a crucial step forward for an often-neglected patient population,” said Dr. Sheryl Kingsberg, chief of behavioral medicine in the Department of Ob/Gyn at University Hospitals Cleveland Medical Center and a co-investigator in the POMPOM study. “Our data shows that this condition is a significant challenge for midlife and menopausal women, but it is treatable. These findings indicate that the Milli dilator is an effective, innovative tool to help our patients improve their quality of life.”

The poster will be presented during The Menopause Society 2025 Annual Meeting, taking place from October 21 to 25, 2025, at the Hyatt Regency in Orlando, FL.